37,700 Shares in Septerna, Inc. $SEPN Acquired by Renaissance Technologies LLC

Posted by Geri Gentry on Aug 15th, 2026

Renaissance Technologies LLC bought a new stake in Septerna, Inc. (NASDAQ:SEPN – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm bought 37,700 shares of the company’s stock, valued at approximately $906,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its holdings in shares of Septerna by 86.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock worth $75,698,000 after acquiring an additional 1,260,409 shares during the period. Vanguard Group Inc. boosted its position in shares of Septerna by 7.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,518,757 shares of the company’s stock worth $28,568,000 after acquiring an additional 104,394 shares in the last quarter. ADAR1 Capital Management LLC increased its stake in Septerna by 38.9% in the third quarter. ADAR1 Capital Management LLC now owns 1,176,491 shares of the company’s stock valued at $22,130,000 after acquiring an additional 329,264 shares during the last quarter. First Light Asset Management LLC acquired a new position in Septerna during the fourth quarter valued at approximately $17,308,000. Finally, VR Adviser LLC raised its position in Septerna by 13.0% during the third quarter. VR Adviser LLC now owns 610,808 shares of the company’s stock valued at $11,489,000 after purchasing an additional 70,355 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $49.00 target price on shares of Septerna in a report on Tuesday. Wells Fargo & Company boosted their price target on Septerna from $48.00 to $50.00 and gave the stock an “overweight” rating in a report on Wednesday. JonesTrading upped their price objective on Septerna from $43.00 to $62.00 and gave the stock a “buy” rating in a research report on Thursday. Stifel Nicolaus set a $49.00 price objective on Septerna in a research note on Tuesday. Finally, Guggenheim lifted their target price on Septerna from $45.00 to $51.00 and gave the company a “buy” rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $51.33.

Check Out Our Latest Stock Report on Septerna

Septerna Price Performance

SEPN stock opened at $44.50 on Friday. The stock has a market cap of $2.08 billion, a price-to-earnings ratio of -82.41 and a beta of 2.29. The company has a 50 day simple moving average of $35.83 and a 200 day simple moving average of $29.64. Septerna, Inc. has a 1 year low of $10.74 and a 1 year high of $51.10.

Septerna (NASDAQ:SEPN – Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.14. The firm had revenue of $26.75 million for the quarter, compared to analyst estimates of $19.22 million. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. On average, equities research analysts anticipate that Septerna, Inc. will post -1.32 EPS for the current fiscal year.

Key Stories Impacting Septerna

Here are the key news stories impacting Septerna this week:

Positive Sentiment: HC Wainwright significantly improved its Septerna earnings outlook, reducing its projected FY2026 loss to $1.15 per share from $2.17 and its FY2027 loss to $1.41 from $3.21. The firm retained a “Buy” rating and a $60 price target, suggesting analysts expect improved financial performance. HC Wainwright forecasts strong price appreciation for Septerna
Positive Sentiment: HC Wainwright also raised its quarterly 2026 and 2027 EPS forecasts, with projected losses narrowing across every period. The revisions indicate better-than-expected operating trends or a more favorable development outlook for the clinical-stage biotechnology company. HC Wainwright earnings estimate revisions
Positive Sentiment: JonesTrading raised its price target from $43 to $62 and assigned a “Buy” rating, while Wells Fargo increased its target from $48 to $50 and maintained an “Overweight” rating. These actions reinforce a favorable Wall Street view following Septerna’s recent earnings beat. JonesTrading raises Septerna price target
Positive Sentiment: Septerna’s latest quarterly results exceeded expectations: the company reported a $0.29-per-share loss versus the anticipated $0.43 loss, while revenue of $26.75 million topped the $19.22 million consensus estimate. Septerna shares rise on better-than-expected earnings
Negative Sentiment: COO Elizabeth Bhatt sold 25,000 shares for approximately $1.1 million at an average price of $44, reducing her ownership by 12.55%. She still holds 174,209 shares, but the insider sale could weigh on sentiment—particularly after the stock’s strong recent advance. Septerna COO insider share sale

Insider Transactions at Septerna

In other news, insider Samira Shaikhly sold 11,798 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $30.06, for a total value of $354,647.88. Following the completion of the transaction, the insider directly owned 793 shares in the company, valued at approximately $23,837.58. This represents a 93.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Daniel D. Long sold 15,000 shares of the firm’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $35.51, for a total value of $532,650.00. Following the sale, the senior vice president directly owned 96,412 shares in the company, valued at approximately $3,423,590.12. This trade represents a 13.46% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 72,828 shares of company stock worth $2,684,314. Corporate insiders own 5.80% of the company’s stock.

Septerna Company Profile

(Free Report)

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.